Please use this identifier to cite or link to this item:
|Title:||Organometallic ruthenium-based antitumor compounds with novel modes of action||Authors:||Ang, W.H.
Mechanism of action
|Issue Date:||1-Mar-2011||Citation:||Ang, W.H., Casini, A., Sava, G., Dyson, P.J. (2011-03-01). Organometallic ruthenium-based antitumor compounds with novel modes of action. Journal of Organometallic Chemistry 696 (5) : 989-998. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jorganchem.2010.11.009||Abstract:||Both metal complexes and organic molecules are widely used for the treatment of various diseases including cancer - in addition to surgery and radiotherapy. Recent years have witnessed a surge of interest in the application of organometallic compounds to treat cancer and other diseases. Indeed, the unique properties of organometallic compounds, intermediate between those of classical inorganic and organic materials provide new opportunities in medicinal chemistry. In this review, based on the award lecture at ICBOMC'10, we describe a class of ruthenium(II)-arene complexes that are weakly cytotoxic in vitro, but show selective antimetastatic activity in vivo. These compounds, [Ru(η6-p-arene)Cl2(pta)] termed RAPTA, interact strongly with proteins, with the ability to discriminate binding to different proteins, but show a relatively low propensity to bind DNA, which is considered to be the main target of many metal-based drugs. The basic RAPTA structure is quite stable in physiological environments, and studies have shown that aquation of the chloride bonds occurs, it may not be an essential step for anticancer drug activity - direct substitution with biomolecular targets is also possible. Based on the favorable physicochemical properties of RAPTA compounds, combined with their highly promising pharmacological properties, the structure represents an ideal scaffold for rational drug design. Thus far, strategies to overcome drug resistance, by interference with critical enzymes responsible for drug deactivation, and tumor targeting, by tethering to human serum albumin via hydrolyzable linkers, have been demonstrated. However, many more approaches can be envisaged. In any case, the net result are a type of hybrid compounds, that occupy a niche somewhere between classical cisplatin-type anticancer agents that are widely applied to many tumor types and targeted therapies based on organic structures used to inhibit specific enzymes. As such, should these compounds prove themselves in the clinic it is not inconceivable that they could be rapidly refined to form personalized chemotherapies. © 2011 Elsevier B.V. All rights reserved.||Source Title:||Journal of Organometallic Chemistry||URI:||http://scholarbank.nus.edu.sg/handle/10635/95569||ISSN:||0022328X||DOI:||10.1016/j.jorganchem.2010.11.009|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 17, 2019
WEB OF SCIENCETM
checked on May 8, 2019
checked on May 14, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.